Abstract Cystic fibrosis (CF) is an autosomal disease associated with malfunction in fluid and electrolyte transport across several mucosal membranes. The most common mutation in CF is an in-frame three-base pair deletion that removes a phenylalanine at position 508 in the first nucleotide-binding domain of the cystic fibrosis conductance regulator (CFTR) chloride channel. This mutation has been studied extensively and leads to biosynthetic arrest of the protein in the endoplasmic reticulum and severely reduced channel activity. This review discusses a novel method of rescuing ΔF508 with transcomplementation, which occurs when smaller fragments of CFTR containing the wild-type nucleotide binding domain are co-expressed with the F508 deletion mutant. Transcomplementation rescues the processing and channel activity of ΔF508 and reduces its rate of degradation in airway epithelial cells. To apply transcomplementation as a therapy would require that the cDNA encoding the truncated CFTR be delivered to cells. We also discuss a gene therapeutic approach based on delivery of a truncated form of CFTR to airway cells using adeno-associated viral vectors.
Introduction
Alterations in the genetic code that either abolish, reduce, change, or enhance protein function cause significant human suffering from a myriad of genetic diseases (Childs and Valle 2000) . A subset of these genetic mutations encode proteins that are transcribed and translated but do not fold properly into a fully functioning proteins (Gregersen et al. 2006) . These misfolded proteins are recognized by the endoplasmic reticulum (ER) quality control machinery (ERAD) and are degraded in proteasomes (Gregersen et al. 2006) . Proteins that bypass the ERAD are diverted into aggresome-related pathways, ultimately being degraded in lysosomes by a process recently dubbed "autophagy" (Luciani et al. 2011) . One of the beststudied proteins in this category is the three-base pair deletion in the cystic fibrosis transmembrane regulator (CFTR) that removes a phenylalanine at position 508 (ΔF508), causing a severe form of cystic fibrosis (CF) (Riordan et al. 1989) . CF is an autosomal recessive disease that is common in Caucasians (Boyault et al. 2006) . Hallmarks of the disease include thick, dehydrated airway mucus, chronic Pseudomonas lung infection, pancreatic insufficiency, bile duct obstruction, infertility in males, reduced fertility in females, high sweat Cl − 1989), which encodes the cystic fibrosis transmembrane regulator (CFTR) (Fuller and Benos 1992) . CFTR is a member of the ATP binding cassette family that functions as both a Cl − channel and conductance regulator. CFTR has two sets of transmembrane domains (TMD) and two nucleotide-binding domains (NBD) (Fig. 1) . It is unique among ABC proteins because it has a regulatory (R) domain whose phosphorylation is the first step in the activation of channel activity (Fuller and Benos 1992) . Once CFTR had been identified, it quickly became clear that the CFTR ΔF508 mutation accounted for the majority of CF patients (Kerem et al. 1990 ). The notion that ΔF508 CFTR is a mutant protein was initially discovered by Cheng and colleagues (Cheng et al. 1990 ). In their report, they concluded that ΔF508 CFTR is recognized by the cell as a mutant protein, retained in the ER, incompletely glycosylated, and subsequently degraded (Fig. 2) . Their study defined the glycosylation pattern of CFTR and divided it into three fractions: fully glycosylated (band C), incompletely glycosylated (band B), and the core protein (band A). The observation that defective processing of ΔF508 CFTR can be partially corrected by low temperature was made by Denning et al. (1992) . They stated that "the mutant protein is not processed correctly and as a result is not delivered to the plasma membrane." Their ground-breaking experiment demonstrated that ΔF508 CFTR undergoes biosynthetic arrest in the ER, and low temperature somehow alleviates this arrest and allows the cell to complete the processing of the mutant CFTR and deliver it to the plasma membrane.
The discovery that ΔF508 CFTR is rapidly degraded by proteasomes was made by Jensen et al. (1995) . They showed that ΔF508 CFTR is sensitive to proteasomal inhibitors and concluded that ∼75 % of the wild-type CFTR and 100 % of the ΔF508 CFTR variant are rapidly degraded before they exit the ER.
One of the first CFTR binding partners to be identified and documented to affect processing of CFTR was the chaperone protein, Hsp70 (Yang et al. 1993) . Wilson and colleagues showed that this protein could be coimmunoprecipitated with CFTR and further demonstrated that Hsp70 normally dissociates from CFTR during the movement to the Golgi. In contrast, Hsp70 remains associated with ΔF508 CFTR in the ER, suggesting that Hsp70 plays a role in blocking ΔF508 CFTR transport out of the ER. This suggestion was novel at the time because it was the first evidence that Hsp70 participated in the processing of a membrane protein. In subsequent studies, Riordan and colleagues also showed that in addition to Hsp70, Hsp90 also plays a role in this process (Loo et al. 1998) . Several other quality control proteins have more recently been added to the list, including CHIP (Alberti et al. 2004; Arndt et al. 2005; Meacham et al. 2001; Younger et al. 2004) and Hdj/Hsc70 (Ahner et al. 2007; Sun et al. 2006; Zhang et al. 2006) The precise steps involved in the qualitycontrol identification of mutant ΔF508 CFTR have been studied extensively but are still not fully understood. Younger et al. (2006) identified an ER membraneassociated ubiquitin ligase complex containing Derlin-1 and the E3 and E2 ubiquitin ligases, RMA1 and Ubc6e, respectively. This complex cooperates with the Hsc70/Chip E3 complex in the degradation of ΔF508 CFTR. The hypothesis is that the RMA1-containing complex evaluates ΔF508 CFTR first, and what escapes is then assessed by Hsc70/ Chip. Both complexes participate in the degradation of ΔF508 CFTR. The conclusion put forward by the authors is that the RMA1 and CHIP E3 ligase complexes monitor the conformation of wild-type (wt) and ΔF508 CFTR and act as a checkpoint. They further noted that any mutant CFTR that escapes the RMA1 checkpoint ultimately fails the CHIP checkpoint.
Once ΔF508 CFTR is recognized as a mutant protein, it must be removed (translocated) out of the ER, a step that requires polyubiquitination by the ligase complexes discussed above and extraction from the membrane by an ATPase associated with diverse cellular activities (AAA ATPase), p97/ valosin-containing protein (VCP) (Ye et al. 2001 ). ΔF508-CFTR is then degraded in the proteasome (Loo et al. 1998 ). In addition to its association with the Derlin 1 complex on the ER membrane, VCP is also found in aggresomes containing ΔF508 CFTR (Kawaguchi et al. 2003) in association with the cytosolic histone deacetylase, HDAC6. These ΔF508 CFTR-containing aggresome bodies are detectable following proteasome inhibition. Thus, once the proteasome is inhibited, CFTR is diverted to the aggresome. It was recently reported that a finely tuned balance between HDAC6 and VCP associated with CFTR determines its fate (Boyault et al. 2006) . The presence of VCP in both the ER-associated complex and CFTR NBD1 NBD2 R TMD2 TMD1 Fig. 1 CFTR is a chloride channel and conductance regular (Schwiebert et al. 1999) . It has two sets of transmembrane domains, two sets of nucleotide binding domains, and a unique R domain (Fuller and Benos 1992) the aggresome, as well as its direct association with the proteasome, indicates that VCP is involved in both retrograde translocation from the ER and presentation of client protein to the proteasome. It has been reported that VCP has a higher affinity for ΔF508 CFTR than for wt CFTR (Vij et al. 2006) , and VCP was recently shown, by means of an endogenous expression system, to be selectively associated with ΔF508 CFTR but not wt CFTR (Goldstein et al. 2007) .
Thus, CFTR's binding to an ensemble of chaperones makes the wt protein more likely to assume a native or nearnative conformation; however, ΔF508 CFTR stalls in the ERresident form. Balch (Coppinger et al. 2012 ) has hypothesized that a network of chaperones and co-chaperones forms a proteostasis network that determines the "success or failure" of protein folding. His group also suggests that ΔF508 CFTR is stalled in a chaperone-bound folding intermediate state that inhibits the folding required to reach the mature state. They hypothesize that altering this network could result in therapeutic rescue. Many investigators have also studied ERAD with the notion that altering it would rescue ΔF508-CFTR.
What is wrong with ΔF508?
Much effort has been expended in attempting to understand the three-dimensional structure of CFTR (Lewis et al. 2004 (Lewis et al. , 2005 (Lewis et al. , 2010 and the impact of the missing phenylalanine at position 508. Thus far, it has proved difficult to obtain crystals of the full-length molecule for X-ray crystallography. Thus, despite great efforts, structures have only been solved for NBD1 and 2. Surprisingly, they show only small perturbations in the overall structure of NBD1, and only in the site bearing the ΔF508 mutation (Lewis et al. 2005) . This was quite a surprise, because up to this point it had been thought that a missing phenylalanine would have a large effect on the whole domain (Thomas et al. 1992) . However, further experimentation showed that the effect was more subtle. Protasevich et al. (2010) was among the first to show that ΔF508 CFTR lowers the unfolding transition temperature of NBD1 by 6-7°C, suggesting that the domain is less stable at physiological temperatures. Consistent with this finding were the limited proteolysis studies of Hoelen et al. (2010) , who showed that NBD1 with and without the ΔF508 CFTR mutation had very similar proteolysis patterns, consistent with the very similar structures identified by Lewis et al. (2004 Lewis et al. ( , 2005 Lewis et al. ( , 2010 . However, ΔF508 was more susceptible to proteolysis than was the wt domain (Hoelen et al. 2010) , consistent with its relative instability.
Many years later, the early work of Teem and his collaborators proved very important for understanding what is wrong with ΔF508, and how the mutation might be corrected. They studied a yeast STE6-CFTR chimera (Teem et al. 1993) . STE 6 is an ABC transporter that moves the a-factor, an essential element in yeast mating (Michaelis 1993) . When they introduced the F508-del mutation into a chimeric STE6-CFTR, the yeast did not mate. Using a mutagenesis approach, they were able to isolate two mutants, R553M and R553Q, which in combination with ΔF508 restored mating. These were referred to as revertant mutants or second-site suppressor mutations (Teem et al. 1993) . A number of investigators have shown that second-site suppressors restore the stability of NBD1 (He et al. 2010; Liu et al. 2012; Mendoza et al. 2012) . For example, Hoelen et al. (2010) , again using a limited proteolysis approach to assess domain stability, showed that an I539T second-site suppressor mutation, in combination with ΔF508 CFTR, restored NBD1 stability to the wt domain pattern, suggesting that correcting NBD1 stability will be critical for the development of a therapeutic for CF. However, it is clear from many studies that only correcting NBD1 stability will most likely not rescue enough ΔF508 CFTR function to be therapeutic, because the missing phenylalanine at position 508 does more than just affect the stability of NBD1 (Choi et al. 2005; Du et al. 2005; Lukacs and Verkman 2012) . Lewis et al. (2010) using mass spectral measurements of backbone amide rates of 1 H/ 2 H exchange, showed that ΔF508 CFTR has increased dynamics, primarily at residues 509-511. His group's results strongly suggested that the F508 deletion causes a defect in an area involved in the contact between NBD1 and the transmembrane domains of CFTR. They also suggested that the increased exposure and dynamics of the 509-511 loop may increase intermolecular interactions that affect the processing of ΔF508 CFTR. Because of the lack of structural information on full-length CFTR, a number of laboratories have developed models based on comparisons with known structures from other ABC transporters (He et al. 2010; Mendoza and Thomas 2007) . These models show clear interactions of the intracellular loops with both NBD1 and 2. For example, experiments with ICL4 indicate that this loop is a critical component of the interaction with NBD1 in the region of F508 (Mendoza et al. 2012) . Indeed, experiments in our group have pointed to R1070 as a particular site of diseasecausing mutations, especially R1070 mutations that result in mis-processing of CFTR (Krasnov et al. 2008) , an outcome that would be expected if this site is important for the domaindomain interactions of ICL4 with a region surrounding F508. Recent experiments have shown that certain amino acid substitutions, namely R1070W in combination with ΔF508 CFTR, can rescue ΔF508 CFTR trafficking, again pointing to the importance of domain-domain interactions in the misprocessing of ΔF508 (Mendoza et al. 2012 ). Thus, a consensus is emerging that the removal of F508 causes a less stable NBD1 that shows defective interactions with ICL4 and perhaps other loops and that both defects lead to classic misfunction (i.e., lower channel activity), the recognition of ΔF508 CFTR as a mutant protein by ERAD, and its subsequent degradation.
Transcomplementation
When certain truncated forms of CFTR are co-expressed with ΔF508 CFTR, the defective function and trafficking of ΔF508 CFTR can be rescued by a process called transcomplementation (Cormet-Boyaka et al. 2004) (Fig. 3) . A very specific subset of CFTR domains must be present for a fragment of CFTR to transcomplement ΔF508-CFTR. Cormet-Boyaka et al. (2004) demonstrated transcomplementation of ΔF508 CFTR with a small fragment of CFTR, 1-633, which contains the complete TMD1 and NBD1. Sun et al. (2008) utilized a smaller fragment that included only NBD1 and the R domain. In our studies (Cebotaru et al. 2008 (Cebotaru et al. , 2013 , we used a truncation missing the first four transmembrane segments of NBD1.
Given the results from these reports, the one common element of all these truncated CFTRs is the presence of the NBD1 domain. Thus, it appears that co-expressing the wt NBD1 domain together with the mutant ΔF508 CFTR can rescue the mutant domain. How does this occur? One theory holds that transcomplementation rescues ΔF508 CFTR via chaperone competition or displacement (Sun et al. 2008 ); a second theory holds that certain truncation mutants bind directly to ΔF508 CFTR and affect its rescue through a bimolecular interaction between the mutant and the truncated wt CFTR molecule.
The chaperone displacement theory
The CFTR fragments that are effective in transcomplementation are by themselves extremely efficiently degraded. Thus, one theory of transcomplementation is that rapidly degraded CFTR fragments overwhelm ERAD (Fig. 4) . Thus, ERAD would be so busy processing the truncation mutants that the processing of ΔF508 CFTR would be less efficient, allowing it to escape the ER and be rescued to the cell surface. Sun et al. have shown that the expression of NBD1 plus the regulatory domain (RD) of ΔF508 CFTR (ΔFRD) also increases the processing of band B to C of ΔF508 CFTR through transcomplementation (Sun et al. 2008) . They showed that Hsp70 and Hsp90 associated equally with WT and ΔF508 CFTR, but almost twice as much of the Hsp90 co-chaperone, Aha1, associated with ΔF508 CFTR. Importantly, they also showed that the expression of ΔFRD produced a dose-dependent removal of Aha1 from ΔF508 CFTR that correlated with its functional rescue. Aha 1 is a cochaperone of Hsp90, which has been identified utilizing proteomics as a key member of the CFTR interactome (Wang et al. 2006) . Interestingly, Aha1 regulates the ATPase activity of Hsp90, and reduction of its activity by RNAi rescues band C of ΔF508 CFTR, allowing it to reach the cell surface. Thus, the suggestion is that the displacement of Aha1 from ΔF508 CFTR by ΔFRD is responsible for the transcomplementation.
We have previously generated an adeno-associated viral gene therapy vector, rAAV-Δ264 CFTR, that is missing the first four transmembrane domains of CFTR (Fischer et al. 2007 ). When infected into monkey lungs, Δ264 CFTR increased the levels of endogenous wt CFTR protein by transcomplementing the endogenous protein. Δ264 CFTR also rescued the processing of the B band to the C band of ΔF508 CFTR by transcomplementation. When Δ264 CFTR plasmid cDNA is transfected by itself into Cos7 cells, protein expression from the truncation mutant is barely detectable when compared to either wt or ΔF508 CFTR (Cebotaru et al. 2008 ). However, Δ264 CFTR protein expression increases dramatically when the cells are treated with proteasome inhibitors, indicating that the reason Δ27-264 CFTR protein expression is barely detectable is that it is being rapidly degraded in the proteasome. Because of this rapid degradation, the steady-state levels of Δ27-264 CFTR are very low. VCP and HDAC6, two proteins involved in retrograde translocation from the ER to the cytosol for proteasomal and aggresomal degradation, coimmunoprecipitate with Δ264 CFTR to a greater extent than with ΔF508 CFTR. Thus, our data are consistent with the idea that by associating with both p97/VCP and HDAC6, Δ264 CFTR affects both the proteasomal degradation and aggresomal accumulation of ΔF508 CFTR, allowing ΔF508 CFTR to be rescued to the cell surface. Consistent with this idea is the observation that, when we inhibit both proteasomes and aggresomes with specific inhibitors of each, rescue of ΔF508 CFTR occurs (Cebotaru et al. 2008) . Thus, it appears that, by avidly engaging the processes involved in the extraction of ΔF508 CFTR from the ER membrane (necessary for proteasome degradation) and in the translocation of mis-folded proteins to the aggresome (necessary for aggresomal degradation), Δ264 CFTR redirects a pool of ΔF508 CFTR out of the ER and toward the maturation of the C band.
Although this is a plausible theory, it cannot explain completely the observation that transcomplementation rescues trafficking and channel activity (Cebotaru et al. 2013 ). As mentioned above, growing cells at a reduced temperature causes a robust trafficking of ΔF508 CFTR out of the ER to the plasma membrane (Denning et al. 1992) . However, the rescued ΔF508 CFTR is still severely defective. Its channel activity is still very low when compared to wt CFTR, and its residence time in the plasma membrane is much shorter than that of wt CFTR (Cebotaru et al. 2013 ). Thus, although ΔF508 CFTR rescued by lowered temperature is released and matures to band C, it is still recognized as a defective protein at the plasma membrane by some of the same mechanisms that operate in the ER to target ΔF508 CFTR for degradation (Ahner et al. 2013 ). This result is not surprising, because, in order to rescue ΔF508 CFTR, both domain stability and interdomain interactions must repaired, and these cannot be restored by temperature rescue Hoelen et al. (2010) . Likewise, it would be difficult for transcomplementing forms of CFTR to rescue the defects in ΔF508 CFTR simply by overwhelming ERAD. These difficulties have led others to postulate that the transcomplementing forms of CFTR are doing more to rescue ΔF508 CFTR. -Boyaka et al. (2004) were the first to show that a truncated version of CFTR binds to and rescues ΔF508 CFTR through a bimolecular interaction (Fig. 5) . We have recently created an improved truncation of CFTR, Δ27-264 CFTR (Fig. 3) , which includes the first 27 amino acids of the Nterminus of wt CFTR. We showed previously that the first 27 amino acids of CFTR are important for enhanced protein expression (Devidas et al. 1998) . Others have demonstrated that the N-terminal tail of CFTR binds to important trafficking molecules such as syntaxin 1a (Naren et al. 1998) . Although Δ27-264 CFTR is still rapidly degraded, it shows higher steady-state levels of detectable protein than does Δ264 CFTR (Cebotaru et al. 2013 ). Δ27-264 CFTR efficiently increases the processing of immature B band to mature C band in both wt and ΔF508 CFTR, as detected by western blotting. Δ27-264 CFTR transcomplements ΔF508 CFTR more efficiently than does Δ264 CFTR (Cebotaru et al. 2013) . It extends the half-life of ΔF508 CFTR and increases the channel activity generated by ΔF508-CFTR. Because Δ27-264 CFTR corrects so many of the defects of ΔF508 CFTR, we tested whether Δ27-264 CFTR actually binds to ΔF508 CFTR and found that it does indeed bind. Thus, Δ27-264 CFTR is likely transcomplementing ΔF508 CFTR via a direct interaction between the two molecules (Fig. 5) .
The molecular interaction theory

Cormet
Where is the binding taking place? As mentioned above, the common feature of the constructs used by us and by CormetBoyaka and colleagues is the presence of the NBD1 . Thus, it is likely that the wt NBD1 is repairing the mutant domain via a direct interaction. It is well known that NBDs from ABC proteins can interact via their Walker domains to hydrolyze ATP (Csanady et al. 2010a; Higgins 1995) . Most of the other ABC transporters function as pumps, actively pumping substances across the cell membrane with energy derived from the hydrolysis of ATP (Holland 2011) . CFTR, on the other hand, is an ion channel that uses its NBDs to alter channel gating, not to transport chloride. Since CFTR is an ion channel, the energy for ion movement is derived from the electrochemical gradient and not from the hydrolysis of ATP (Csanady et al. 2010b ). CFTR does still hydrolyze ATP exclusively via its Walker 2 site (Lewis et al. 2004 ). Thus, the two NBDs still closely interact to regulate gating (Powe et al. 2002) . The question that remains is whether the wt NBD from a truncated CFTR can interact directly with the mutant domain and repair it.
As mentioned above, isolated NBD domains have been crystallized (Lewis et al. 2004) . A unique feature of the NBD1 from CFTR is the 30-residue insertion near the Nterminus of NBD1, termed the RI (regulatory insert), and a 30-residue extension at the C-terminus, called the RE (regulatory extension). Both contain sites for PKA phosphorylation, suggesting that they may regulate CFTR function (Lewis et al. 2004 ). However, even though RE and RI are unique structural components, their function is unknown. Interestingly, NBD1 can form a crystal dimer (Atwell et al. 2010) in the absence of RI. Thus, at least in this assay system, it is possible for NBD1 to interact with itself under certain circumstances, making it feasible to postulate that transcomplementation occurs via an ΔF508 is recognized as a mutant protein and degraded in the proteasome. Small amounts may reach the plasma membrane but the defective channel has reduced channel gating, not enough to support normal physiological function (Fuller and Benos 1992) interaction between NBDs from two different molecules. wt CFTR has been show to function as a monomer (Chen et al. 2002) , but there is evidence that it functions more efficiently as a dimer (Wang et al. 2000) . Given that dimerization of CFTR may be a natural state for the efficient function of CFTR, it is plausible that transcomplementation could occur via the direction interaction between the mutant and wt NBD1. It is also possible that, because these transcomplementing truncations
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Gene therapy
To apply transcomplementation as a therapy would require that the cDNA encoding the truncated CFTR be delivered to cells via a gene therapeutic approach. Since shortly after the identification of the CF gene, our group has been devoted to the idea of developing a gene therapy for CF. Many groups have experimented with gene therapeutic approaches for CF and have run into significant hurdles that have reduced their efforts in this area (Flotte 1999) . Despite the problems with other virus-based gene therapy vectors, recombinant adenoassociated viral (rAAV) vectors hold significant promise for gene transfer in humans. AAV is a nonpathogenic parvovirus (see Carter 1996; Berns and Giraud 1995 for reviews). Its replication is generally dependent on co-administration with a helper virus, usually an adenovirus or a herpesvirus. Infection with wt virus may include stable integration of the AAV genome into the AAVS1 site on chromosome 19 (Kotin et al. 1990 ). The AAV genome is a 4.68-kb, linear single strand of DNA consisting of inverted terminal repeats (ITR) and rep and cap (see Carter and Flotte 1996 for a review). ITRs consist of 145-bp stretches of DNA and are absolutely required for the integration, replication (ori), excision, and packaging of the virus. The cap gene is required for encapsidation. There are three cap proteins, produced by alternate splicing. The rep gene is involved in replication, and there are four rep proteins, also produced by alternate splicing. Deletion of the AAV rep gene, required for replication (Snyder et al. 1993) , results in a loss of the site specificity of the integration (Kearns et al. 1996) . However, it has been shown that, even with the rep deletion, AAV vectors are capable of long-term persistence through random-site integration and episomal persistence (Duan et al. 1998) . A number of serotypes have been identified (Gao et al. 2005) with preferred tropism for different organs in the body. Also, a number of groups have generated novel capsids not found in nature that improve the tropism for specific tissues (Zhong et al. 2008 ). rAAV vectors transduce a variety of cell types in several animal models, including rabbit and monkey lung (Beck et al. 1999 (Beck et al. , 2002 . In a phase I clinical trial, airway delivery to CF patients was safely accomplished by nebulization of aerosolized AAV2-CFTR vector (Wagner et al. 1998b) . In a phase I/II clinical trial, AAV-CFTR delivery to the maxillary sinuses of CF patients resulted in dose-dependent gene transfer and a functional correction of the transepithelial potential difference (Wagner et al. 1998a) . A study using CF patients given three repeat aerosolized doses of 1×10 13 DNAse-resistant particles of tgAAVCF showed significant improvement in FEV 1 at day 30, and induced sputum IL-8 levels on days 14-45 (Moss et al. 2003) . However, in a large study, the clinical significance was not repeated (Moss et al. 2003) .
AAV is a single-stranded DNA virus that must be converted to double-stranded form for gene expression (see Sanlioglu et al. 2001) . Studies have shown that this conversion does take place, albeit slowly, in non-dividing cells (Boyle et al. 2001) . AAV is unique among the DNA viruses in that it is defective for replication and undergoes site-specific stable integration ER ΔF508 + Wt NBD1
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ΔF508 CFTR Δ27-264 CFTR Fig. 5 Δ27-264 may act as a molecular chaperone by binding to ΔF508 and allowing it to fold properly restoring its native function. Binding is likely to occur via the NBD1 domains because the NBD1 domain is a common requirement for transcomplementation to occur into human chromosome 19 (Kotin et al. 1992; Samulski 1993) . Studies looking at the fate of rep-deleted vector DNA indicate, however, that the DNA is located episomally or integrated randomly at a low frequency (Duan et al. 1998 ). Thus, the issue of persistent expression after a single dose to epithelial cells, which have a finite life span, is a key question when one considers an eventual therapeutic benefit from gene therapy. Although the clinical phase I study of a single dose of vector to the maxillary sinuses demonstrated evidence of gene transfer for 10 weeks, loss of protein expression was noted by day 28 (Wagner et al. 1999) . Thus, it is likely that the maintenance of sufficient recombinant CFTR expression would require repeated administration over the lifetime of the patient. Serial-dosing strategies for gene therapy vectors are known to elicit an escalating humoral immune response to the recombinant vector, to either the foreign transgene or the viral capsid proteins, that is inhibitory to gene transfer (Halbert et al. 1997) . It has been suggested that this immune response poses a significant barrier to repeated delivery of AAV vectors.
In terms of immunogenicity to AAV, natural AAV2 infection is quite common in humans, with over 50-80 % of adults being seropositive for AAV2 by complement fixation (Chirmule et al. 1999; Monahan and Samulski 2000) . However, other serotypes are less common in humans, making these alternative serotypes more amenable for human gene therapy (Beck et al. 1999b; Gao et al. 2005) . Experiments have shown that repeated delivery of rAAV vectors to the airways of rabbits and monkeys does not cause a significant inflammatory response despite repeated exposure (Beck et al. 1999a ). This finding is consistent with the observations in humans that re-exposure to wt AAV infection does not result in clinically significant inflammation or protective immunity and that re-dosing of rAAV2 CFTR in CF patients is not harmful (Moss et al. 2003) , lending support to the claim that serial re-administration of rAAV CFTR vectors in humans is very feasible and can have therapeutic benefit.
Although promising, the data from all these clinical trials have demonstrated that gene transduction by AAV vectors derived from serotype 2 is inefficient. Several studies have consistently shown this inefficiency (Halbert et al. 1995; Sanlioglu et al. 2001) . It has been suggested that one reason that AAV2-based vectors transduce inefficiently is the lack of viral receptors on the apical surface (Duan et al. 2000) . For example, Engelhardt and colleagues showed that AAV2 transduces the basolateral surface of airway epithelia 200-fold more efficiently than the apical membrane (Duan et al. 2000) and that this difference is correlated with the abundance of the AAV-2 receptor, heparan sulfate proteoglycan, on the basolateral surface (Sanlioglu et al. 2001) . Although their data are consistent with the relative paucity of viral receptors and co-receptors in the apical membrane of airway epithelial cells, Engelhardt and collaborators subsequently showed that human airway epithelia do actually internalize AAV2 virus efficiently across the apical cell membrane. Surprisingly, the lower transduction efficiency following apical application of vector is caused by differences in endosomal processing and nuclear trafficking of recombinant virus particles taken across the apical cell membrane (Duan et al. 2000) . Apparently, AAV2 capsid proteins are avidly ubiquitinated and degraded after endocytosis across this membrane. Importantly, inhibition of degradation by tripeptide proteasome inhibitors was able to increase the viral transduction, when virus was delivered across the apical membrane, to a level nearly equivalent to that achieved with basolateral infection. Thus, whether it is the result of a relative paucity of receptors or targeted degradation via apically oriented endocytosis, significant protein expression from rAAV2 vectors clearly does occur, but it requires highly efficient delivery of large quantities of pure recombinant particles.
Given the promise of AAV vectors for gene therapy, the ability to increase their transduction is needed before utilization as a therapy is feasible. The major challenges in moving forward are three-fold: identification of serotypes that are more trophic for the lung; inclusion of a more powerful promoter to boost the expression of CFTR; and effective truncation of the molecule to accommodate the rather small packaging capacity of AAV.
Testing of new serotypes was made easier by our observation that it was feasible to use pseudotyped vectors containing the ITR from AAV2 but the capsid from other serotypes, making it easier to test different seroytpes without altering the ITR2-CFTR constructs. Thus, the packaging plasmid containing the Rep genes with the alternate capsid sequence (Beck et al. 1999a ) could be altered without having to change the ITR2-CFTR construct. Using this approach, we have shown that AAV5-based vectors are more effective than AAV2 in the airways (Fischer et al. 2007) . Recently, AAV1, another member of the parvovirus family, has received a lot of attention because of its enhanced tropism in human airway cells (Kaludov et al. 2001; Zabner et al. 2000) . To determine whether this serotype transfers gene efficiently, we developed a method using Renilla luciferase (RL) and firefly luciferase (FL) reporters to compare in the same animal the relative transduction efficiency and immune response to different recombinant AAV serotypes. The two reporter genes were packaged into different serotypes, admixed, and administered to non-human primates using a microsprayer (Flotte et al. 2010) . Analysis of differential luciferase activity in chimpanzee airway brushings revealed a 20-fold higher efficiency of rAAV1 over rAAV5 at 90 days, a finding paralleled in polarized human airway epithelia. Interestingly, T-cell responses to the AAV1 capsid were much lower than those to the AAV5 capsid, making AAV1 a very promising vector delivery system for the human CF airway.
Another limitation of AAV vectors is their small size, which is at its packaging limit with CFTR (Berns and Giraud 1995) . Several years ago, we reported that the ITR itself can mediate gene expression (Flotte et al. 1993) . In stable transfection assays, we showed that AAV-CFTR vectors expressing full-length CFTR cDNA restored cAMP regulation of the chloride efflux characteristic of CFTR function. These studies uncovered a novel promoter in the ITR that allowed for the production of AAV vectors expressing the fulllength CFTR currently used in gene therapy trials for CF. Although these vectors are useful for expressing CFTR, the expression levels are not robust and could contribute to the difficulty that has been experienced in detecting gene expression in in vivo gene therapy experiments. To overcome this problem, a new powerful promoter was developed (Mueller and Flotte 2008 ) that enhances the expression of CFTR. This chicken beta-actin promoter remains active for long periods, solving the problem of promoter silencing noted with the CMV promoters (Sirninger et al. 2004 ). However, because of the large size of the CFTR gene (4.5 kb), it is not possible (because of the packaging limitations of the 4.7-kb AAV) to use AAV to generate constructs containing full-length CFTR. Therefore, partially deleted versions of CFTR have had to be developed, such as Δ27-264 CFTR. In the course of developing these truncated versions of CFTR, we discovered transcomplementation as a novel way of combining gene therapy with protein repair therapy. Thus, instead of inserting a new copy of the CF gene into patients, gene therapy with the truncated forms of CFTR studied here would repair the native protein. Although gene therapy will target multiple cells in the airway, since transcomplementation acts directly on ΔF508 CFTR, it would fix the endogenous CFTR in the relevant cells. Also, since the truncated forms of CFTR, Δ27-264 and Δ264, do not have intrinsic channel activity, they would not function independently in non-relevant cells. However, given that the transcomplementing forms of CFTR are actively degraded, one question is whether the expression of a rapidly degraded protein would induce a cell stress response. However, extensive studies with Δ264 CFTR in rhesus monkeys have not uncovered any adverse events in the animals, even though truncated recombinant protein expression was detected and transcomplementation of the endogenous wt CFTR protein was observed. Thus, if stress is occurring, it does not have any clinical effect.
Given this evidence that transcomplementation can rescue ΔF508 CFTR, along with the extrapolation of in vitro studies suggesting that only a small 5-10 % correction is required to overcome the CF chloride ion transport defect in cultured CF airway epithelium (Knowles et al. 1995) , it is feasible to expect that gene therapy has great potential to become a practical intervention for CF, providing that vector-derived expression of CFTR is maintained over time.
ΔF508 processing through a biomolecualr interaction. J Biol Chem 288:10505-10512. PM:23463513. The work showed that one mechanism whereby transcomplementation could occur is by the binding of mutant ΔF508-CFTR which contains NBD1 missing phenylalanine at position 508 with a truncated from of CFTR which contains a normal NBD1
